Precision medicine is now firmly entrenched in the fertility services market, exemplified by the increasing utilization of Preimplantation Genetic Testing (PGT). PGT is a powerful diagnostic tool that allows embryologists to screen embryos for chromosomal abnormalities (aneuploidy) and specific genetic disorders before implantation. This technique is revolutionizing success rates, particularly for women of advanced maternal age, and significantly reducing the risk of miscarriage associated with genetic issues. The ability to select only genetically healthy embryos for transfer has become a game-changer in the industry.

The incorporation of PGT is a critical factor driving the success rate of In Vitro Fertilization (IVF), which remains the dominant procedure, holding an 87% market share in 2023. By enhancing the selection process, PGT contributes to higher implantation rates and an increase in healthy live births. The American Society of Reproductive Medicine reported in 2024 that approximately 2.5% of all births resulted from successful Assisted Reproductive Technology (ART) cycles, a testament to the effectiveness of these advanced techniques. The increasing demand for this precision is a core driver for the overall market’s robust growth. For a detailed perspective on how these cutting-edge preservation and screening techniques are transforming clinical practices and influencing market dynamics, a critical report on advanced cryopreservation market trends offers necessary context.

Furthermore, innovation in cryopreservation, often utilized in conjunction with PGT, is improving treatment flexibility. Techniques like vitrification have made it possible to freeze and store embryos after PGT testing with exceptionally high viability. This allows for Frozen Embryo Transfer (FET) cycles, which can be timed more optimally for the patient’s uterine environment, contributing further to positive outcomes.

The commitment to genetic precision highlights the fertility services market's trend toward offering highly individualized and effective treatments. As PGT technology becomes more accessible and refined, its role as a fundamental component of high-success-rate ART cycles will solidify its position as a primary contributor to the market’s projected expansion to over USD 137 Billion by 2035.